Table 2. Antiangiogenetic therapies for patients newly diagnosed with ovarian cancer
From: Ovarian cancer standard of care: are there real alternatives?
| Therapy | Agent | Trial | Number of patients | Armsa | Primary endpoint | Results |
|---|---|---|---|---|---|---|
| Combination with chemotherapy | Bevacizumab | GOG218[41] | 1,873 | CP × 6 + Pl → Pl | PFS | Prolonged PFS, max PFS benefit (Pl group vs. Bm group, 18 vs. 12 months, hazard ratio = 0.64, P < 0.001) |
| CP × 6 + B (15 mg/m2) | ||||||
| CP × 6 + B→Bm (15 mg/m2) | ||||||
| ICON7[42] | 1,528 | CP × 6 | PFS | Prolonged PFS (17.3 vs. 19 months, P = 0.004) | ||
| CPB × 6→Bm (7.5 mg/m2) | ||||||
| Nintedanib | AGO-OVAR 12[57] | 1,366 | CP × 6 | PFS | Prolonged PFS (16.6 vs. 17.3 months, P = 0.024) | |
| CPB × 6 + N | ||||||
| Maintenance | Pazopanib | AGO-OVAR 16[54] | 940 | CP × ⩾ 5 → Pl | PFS | Prolonged PFS (12.3 vs. 17.9 months, P = 0.002) |
| CP × ⩾ 5 → Paz m |